IL30235A - 10alpha-alkoxy-9,10-dihydroergoline derivatives - Google Patents
10alpha-alkoxy-9,10-dihydroergoline derivativesInfo
- Publication number
- IL30235A IL30235A IL30235A IL3023568A IL30235A IL 30235 A IL30235 A IL 30235A IL 30235 A IL30235 A IL 30235A IL 3023568 A IL3023568 A IL 3023568A IL 30235 A IL30235 A IL 30235A
- Authority
- IL
- Israel
- Prior art keywords
- group
- structural formula
- carbon atoms
- hydrogen atom
- derivatives
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- -1 benzyl isobutyl Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002908 adrenolytic effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- YDOTUXAWKBPQJW-UHFFFAOYSA-N ergocryptine Chemical compound C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=CNC3=C1 YDOTUXAWKBPQJW-UHFFFAOYSA-N 0.000 description 3
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 3
- 229960004943 ergotamine Drugs 0.000 description 3
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 1
- 229960004290 dihydroergocornine Drugs 0.000 description 1
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 1
- 229960004318 dihydroergocristine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- OWEUDBYTKOYTAD-MKTPKCENSA-N ergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@@H]1C=C2C3=CC=CC4=NC=C([C]34)C[C@H]2N(C)C1)C(C)C)C1=CC=CC=C1 OWEUDBYTKOYTAD-MKTPKCENSA-N 0.000 description 1
- HEFIYUQVAZFDEE-UHFFFAOYSA-N ergocristinine Natural products N12C(=O)C(C(C)C)(NC(=O)C3C=C4C=5C=CC=C6NC=C(C=56)CC4N(C)C3)OC2(O)C2CCCN2C(=O)C1CC1=CC=CC=C1 HEFIYUQVAZFDEE-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1775067 | 1967-06-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL30235A0 IL30235A0 (en) | 1968-08-22 |
| IL30235A true IL30235A (en) | 1972-05-30 |
Family
ID=11150913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL30235A IL30235A (en) | 1967-06-28 | 1968-06-24 | 10alpha-alkoxy-9,10-dihydroergoline derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US3585201A (en, 2012) |
| AT (1) | AT279059B (en, 2012) |
| BE (1) | BE717272A (en, 2012) |
| CH (1) | CH513175A (en, 2012) |
| DK (1) | DK118291B (en, 2012) |
| ES (1) | ES355553A1 (en, 2012) |
| FI (1) | FI48190C (en, 2012) |
| FR (2) | FR7775M (en, 2012) |
| GB (1) | GB1158530A (en, 2012) |
| IL (1) | IL30235A (en, 2012) |
| NL (1) | NL142954B (en, 2012) |
| NO (1) | NO123225B (en, 2012) |
| SE (1) | SE337035B (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7400790A (en, 2012) * | 1973-02-02 | 1974-08-06 | ||
| YU216177A (en) * | 1977-09-09 | 1984-02-29 | Rudolf Rucman | Process for preparing 2-bromo ergosine |
| IT1213206B (it) * | 1984-08-07 | 1989-12-14 | Inverni Della Beffa Spa | Procedimento per la preparazione di derivati del lisergolo. |
-
1968
- 1968-06-15 FR FR156426A patent/FR7775M/fr not_active Expired
- 1968-06-17 NL NL686808493A patent/NL142954B/xx unknown
- 1968-06-24 FI FI681766A patent/FI48190C/fi active
- 1968-06-24 FR FR1569450D patent/FR1569450A/fr not_active Expired
- 1968-06-24 IL IL30235A patent/IL30235A/en unknown
- 1968-06-24 NO NO2490/68A patent/NO123225B/no unknown
- 1968-06-25 AT AT607168A patent/AT279059B/de not_active IP Right Cessation
- 1968-06-25 DK DK301168AA patent/DK118291B/da unknown
- 1968-06-25 GB GB30193/68A patent/GB1158530A/en not_active Expired
- 1968-06-26 US US740108A patent/US3585201A/en not_active Expired - Lifetime
- 1968-06-27 ES ES355553A patent/ES355553A1/es not_active Expired
- 1968-06-27 SE SE08721/68A patent/SE337035B/xx unknown
- 1968-06-27 BE BE717272D patent/BE717272A/xx unknown
- 1968-06-27 CH CH956768A patent/CH513175A/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH513175A (de) | 1971-09-30 |
| FR7775M (en, 2012) | 1970-03-23 |
| FI48190B (en, 2012) | 1974-04-01 |
| ES355553A1 (es) | 1969-12-01 |
| AT279059B (de) | 1970-02-25 |
| FI48190C (fi) | 1974-07-10 |
| NL142954B (nl) | 1974-08-15 |
| GB1158530A (en) | 1969-07-16 |
| NL6808493A (en, 2012) | 1968-12-30 |
| FR1569450A (en, 2012) | 1969-05-30 |
| NO123225B (en, 2012) | 1971-10-18 |
| DE1770699A1 (de) | 1972-03-16 |
| IL30235A0 (en) | 1968-08-22 |
| DK118291B (da) | 1970-08-03 |
| US3585201A (en) | 1971-06-15 |
| DE1770699B2 (de) | 1975-06-05 |
| SE337035B (en, 2012) | 1971-07-26 |
| BE717272A (en, 2012) | 1968-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI22888A (sl) | Polimorfi donepezil hidroklorida in postopek izdelave | |
| SI9720038A (sl) | Polimorfi donepezil hidroklorida in postopek izdelave | |
| US4219555A (en) | 2-Bromoergosine and pharmacologically compatible acid addition salts thereof as well as their use for the treatment of arterial hypertension and or heart arrythmias | |
| FR2466465A1 (fr) | Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant | |
| SU1308196A3 (ru) | Способ получени 5,11-дигидро-11- @ (1-метил-4-пиперидинил)-амино @ -карбонил @ -6 @ -дибенз ( @ , @ )азепин-6-она или его солей | |
| WO2013095708A1 (en) | Novel neuromodulatory compounds | |
| IL30235A (en) | 10alpha-alkoxy-9,10-dihydroergoline derivatives | |
| JPS5813542B2 (ja) | シンキエルゴリンユウドウタイノ セイホウ | |
| US3966745A (en) | Vinvamine series cycloalkyl-alkyl esters | |
| JPS58159492A (ja) | コリナンテイン誘導体、その製造方法およびその用途 | |
| US3228944A (en) | Lumiergoline derivatives | |
| IE912362A1 (en) | 3-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)- 3H-imidazo [4,5-b]-pyridin-2-amine 2-hydroxy-1,2,3-propanetricarboxylate | |
| US4285949A (en) | Vincamine derivatives, their preparation and therapeutical use | |
| US4026902A (en) | Isoxazole derivatives | |
| US4279916A (en) | Method of treatment using new leurosine derivatives | |
| US3328424A (en) | 1-isopropylamino-2-hydroxy-3-(2'-isopropoxy-phenoxy)-propane and salts thereof | |
| KR880001865B1 (ko) | 4-(1-이미다졸일메틸)신남산 하이드로클로라이드 모노하이드레이트의 제조방법 | |
| US4440772A (en) | Acid addition salts of dextrorotatory ergot alkaloids, a process for the preparation thereof as well as their use as medicines | |
| CN107540677B (zh) | 一种西格列汀衍生物或其药学上可接受的盐及其制备方法和应用 | |
| US3005818A (en) | 1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds | |
| US3592816A (en) | N-substituted piperazides of lysergic acid | |
| US4028371A (en) | The compound 1,3,4-trimethyl-1-(3,4,5-trimethoxybenzyl)-1,2,5,6-tetrahydropyridine chloride | |
| NL8003318A (nl) | Ergopeptinederivaten en werkwijze voor het bereiden van deze derivaten en van geneesmiddelen die deze deriva- ten bevatten. | |
| CS199258B2 (en) | Process for preparing new antibiotic compounds of rifamycine-s,substituted in 3 position by aliphatic substituted aminogroup | |
| US2753340A (en) | Maleate salts of protoveratrine a and protoveratrine b |